Group 1 - The Shanghai Composite Index fell by 0.46% to close at 3666.44 points, while the Hang Seng Index decreased by 0.37% to 25519.32 points [1] - Fudan Zhangjiang's A/H share premium reached 195.57%, ranking second among A/H shares [1] - At market close, Fudan Zhangjiang's A-shares were priced at 10.24 yuan, down 3.31%, and H-shares were at 3.79 HKD, down 3.32% [1] Group 2 - Fudan Zhangjiang Biopharmaceutical Co., Ltd. was established in November 1996 in the Zhangjiang Hi-Tech Park, Shanghai, with notable shareholders including Shanghai Pharmaceuticals Holding Co., Ltd. [1] - The company focuses on innovative research, development, production, and sales in the biopharmaceutical sector, aiming to become a knowledge-based innovation enterprise [1] - Fudan Zhangjiang has developed competitive advantages in areas such as gene technology drugs, photodynamic therapy drugs, nanotechnology drugs, and oral solid dosage forms, with new drugs expected to be launched in the market [1]